Skip to content
POM-V Prescription Required Companion Animal

Tsefalen 1000 mg Film-coated Tablets for Dogs

Active ingredient: Cefalexin

Form

Tablet

Species

Dogs

Manufacturer

Nextmune Italy S.R.L.

VMD MA No.

58047/4001

What it's used for

Pharmacodynamics Cefalexin is an antibacterial belonging to the group of antibiotics, and is structurally analogous to and has similar mode of action to pe...

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Cefalexin

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Tsefalen 1000 mg Film-coated Tablets for Dogs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Pharmacodynamics
Cefalexin is an antibacterial belonging to the group of antibiotics,
and is structurally analogous to and has similar mode of action to penicillins.
It belongs to the first generation of cephalosporins.
The β-lactam
inhibition of transpeptide and carboxypeptide enzymes, causing an osmotic
imbalance that destroys growing bacteria. Cefalexin is active against gram-
positive bacteria such as Staphylococcus aureus (including betalactamase-
producing strains), other staphylococci which do or do not produce penicillinases,
and
spp., including
Critical concentrations (cutting points or breakpoints) sensitivity (S) and
resistance (R), in µg/ml, for first generation cephalosporins (CLSI, 2013):
Susceptible: ≤≥ 32. The main mechanisms of
resistance against beta-lactams are the production of enzymes (beta-
lactamases) that inactivate the drug, the alteration of penicillin-fixing proteins and
the alteration of the permeability of the bacterial outer membrane. Cephalosporins
are generally not sensitive to the action of beta-lactamases.
There is a cross-resistance (involving the same resistance mechanism) between
antibiotics of the beta- lactam group due to structural similarities. It occurs with
beta-lactamase enzymes, structural changes in porins, or changes in efflux
pumps. Co-resistance (involving different resistance mechanisms) has been
described in E.coli due to the fact that a plasmid carries various genes encoding
resistance.
The recommended dose is 15 mg of cefalexin per kg of body weight twice a day (i.e.
equivalent to one tablet twice a day for a dog weighing 66 kg). In severe or acute
conditions, the dose may be doubled to 30 mg/kg twice daily.
The following is a guide for the use of the veterinary medicinal product:
Bodyweight
min kg
Bodyweight
max kg
Number of
tablets per
dose*
41.066.0166.180.01.5
*Dose to be given twice per day
Animals weighing more than 81 kg bodyweight should be administered an
appropriate combination of tablets according to bodyweight.
The veterinary medicinal product must be administered for a minimum of 5 days.
-
-
-
Any increase in dose or duration of treatment should be accordingly to a benefit/risk
assessment by the responsible veterinarian (e.g. chronic pyoderma).
To ensure a correct dosage body weight should be determined as accurately as
possible.
The veterinary medicinal product can be given as whole tablets or crushed and
added to food if necessary.
Do not use in cases of hypersensitivity to the active substance, to other
cephalosporins, to other substances of the beta lactam group or to any of the
excipients.
Do not use in rabbits, gerbils, guinea pigs, and hamsters.
Dogs:
Rare
(1 to 10 animals / 10,000
animals treated):
Hypersensitivity reaction
. Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Nausea, vomiting, diarrhoea.
In cases of hypersensitivity reactions the treatment should be discontinued.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.
None.

Special precautions for safe use in the target species:
Wherever possible, use of the veterinary medicinal product should be based on
susceptibility testing of the bacteria isolated from the animal and take into account
official and local antimicrobial policies.
Deviating from the instructions given in the SPC when using the veterinary medicinal
product may increase the prevalence of bacteria resistant to cefalexin and may also
decrease the effectiveness of other beta-lactam antimicrobial treatments, due to the
potential for cross-resistance. Therefore, deviation from the instructions must only be
undertaken according to a risk/benefit assessment by the responsible veterinarian.
Do not administer in cases of known resistance to cephalosporin and penicillin.
As with other antibiotics which are excreted mainly by the kidneys, systemic
accumulation may occur when renal function is impaired. In case of known renal
insufficiency the dose should be reduced, and antimicrobials known to be nephrotoxic
should not be administered concurrently.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Penicillins and cephalosporins may cause sensitisation (allergy) following injection,
inhalation, ingestion, or skin contact. Sensitivity to penicillins may lead to cross-
sensitivity to cephalosporins and vice versa. Allergic reactions to these substances
may occasionally be serious. Do not handle this veterinary medicinal product if you
know you are sensitised or if you have been advised not to be in contact with such
substances.
Handle this veterinary medicinal product with great care to avoid exposure, taking all
recommended precautions. If you develop symptoms following exposure such as skin
rash, you should seek medical advice and show the doctor this warning. Swelling of
AN: 00536/2024 & 00537/2024
the face, lips or eyes or difficulty breathing are more serious symptoms and require
urgent medical attention.
In case of accidental ingestion, seek medical advice immediately and show the
package leaflet or the label to the physician.
Wash hands after use.
Special precautions for the protection of the environment:
Not applicable.
In order to ensure efficacy, the veterinary medicinal product should not be used in
combination with bacteriostatic antibiotics.
Concurrent use of first generation cephalosporins with polypeptide antibiotics,
aminoglycosides or some diuretics such as furosemide can enhance nephrotoxicity
risks.
AN: 00536/2024 & 00537/2024
This veterinary medicinal product does not require any special temperature conditions.
Return any halved tablet to the blister pack.
Not applicable.
AN: 00536/2024 & 00537/2024
4.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.